Pharma Pulse 12/16/24: Learning from Other Industries, Another Ailment That Semaglutide Might Help With & more

Peer Exchange: Learning from Other Industries (Episode 4)

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success.

Knee Pain: Another Ailment That Semaglutide Might Help With

A study published in The New England Journal of Medicine has demonstrated the potential of semaglutide for alleviating knee osteoarthritis pain in obese individuals in addition to weight loss. Participants treated with semaglutide, sold under the name Ozempic for diabetes and Wegovy for weight loss, experienced a significantly greater reduction in body weight compared to those receiving a placebo while also achieving substantially decreased knee osteoarthritis pain and improved physical function.

Why Hackers Want Your Health Information

Health records contain personal information that can leave patients exposed to financial and medical risks.

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Sciences, Inc. announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.

Elevar Therapeutics on LinkedIn

We are thrilled to be listed among leading global healthcare companies as a winner of the 2024 Pharmaceutical Executive APEX Awards. Elevar’s "Explore HCC" campaign won for best #Oncology Disease Education & Awareness Campaign. Congratulations to Erin Shubert, Neena O’Connell, PMP and The Agency Network at MJH Life Sciences. Check out Explore HCC: https://explorehcc.com/ #ElevatingOutcomes #APEXAwards #uHCC

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs